Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study (Q89195822)
Jump to navigation
Jump to search
scientific article published on 29 June 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study |
scientific article published on 29 June 2016 |
Statements
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study (English)
K Kaku
K Enya
R Nakaya
T Ohira
1 reference